SGLT2抑制剂联合GLP-1受体激动剂在2型糖尿病中的有效性与安全性:队列研究的系统综述与Meta分析
本系统综述与Meta分析纳入18项队列研究共1,164,774例2型糖尿病患者,比较SGLT2抑制剂联合GLP-1受体激动剂与单药治疗的心肾结局。联合治疗与较低的主要不良心血管事件、全因死亡、心血管死亡、心衰住院及肾脏复合终点风险相关,安全性事件无差异,但证据确定性较低。
要点
- 联合治疗较单药降低MACE风险(RR 0.56),证据确定性低。
- 联合治疗降低全因死亡(RR 0.50)和心血管死亡(RR 0.26)风险。
- 心衰住院风险降低(RR 0.67),证据确定性中等。
核心结论
- 观察性研究提示,SGLT2抑制剂联合GLP-1受体激动剂较单药治疗可能降低2型糖尿病患者MACE、全因死亡、心血管死亡、心衰住院及肾脏复合终点风险。
- 残余混杂无法排除,结果支持未来开展联合与单药对比的随机对照试验。
研究设计与样本
- 系统检索PubMed和Embase自建库至2025年5月1日的队列研究,比较联合治疗与SGLT2抑制剂或GLP-1受体激动剂单药治疗对(心血管)死亡及心血管或肾脏终点的影响。
- 排除1型糖尿病研究及随访不足1年的研究,最终纳入18项队列研究共1,164,774例参与者。
- 采用ROBINS-I评估偏倚风险,随机效应Meta分析合并风险比(RR)及95%CI,GRADE评估证据确定性。
主要发现
- 联合治疗与较低MACE风险相关(RR 0.56 [95% CI 0.43, 0.71];低证据确定性)。
- 联合治疗与较低肾脏复合终点风险相关(RR 0.48 [95% CI 0.32, 0.73];极低证据确定性)。
- 联合治疗与较低全因死亡风险(RR 0.50 [95% CI 0.40, 0.63];低证据确定性)和心血管死亡风险(RR 0.26 [95% CI 0.16, 0.43];低证据确定性)相关。
- 联合治疗与较低心衰住院风险相关(RR 0.67 [95% CI 0.64, 0.71];中等证据确定性)。
- 安全性数据因事件缺乏无法合并,严重低血糖、糖尿病酮症酸中毒、泌尿生殖系统感染及胃肠道副作用风险未见差异;未报告严重不良事件或主要不良肢体事件数据。
临床怎么用
- 对于2型糖尿病患者,在考虑心肾获益时,SGLT2抑制剂与GLP-1受体激动剂联合治疗可能较单药治疗进一步降低心血管和肾脏事件风险。
- 联合治疗未观察到严重低血糖、酮症酸中毒、感染或胃肠道副作用风险增加,但证据来自观察性研究,需结合患者个体情况决策。
局限性
- 纳入研究均为观察性队列研究,残余混杂无法排除。
- 部分结局证据确定性低或极低。
- 安全性数据因事件缺乏无法合并,且未报告严重不良事件和主要不良肢体事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiorenal risk in type 2 diabetes. However, the effect of combining these drugs remains uncertain. This systematic review aimed to evaluate the potential effectiveness and safety of combination therapy compared with monotherapy in individuals with type 2 diabetes. METHOD: We systematically searched PubMed and Embase from inception to 1 May 2025 for cohort studies comparing the effect of combination therapy with SGLT2 inhibitor or GLP-1 RA monotherapy on (cardiovascular) mortality and cardiovascular or kidney endpoints in individuals with type 2 diabetes. Studies enrolling individuals with type 1 diabetes or a maximum follow-up of less than 1 year were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE). Secondary outcomes included all-cause mortality, cardiovascular mortality, hospitalisation for heart failure, a kidney composite endpoint and serious adverse events. Risk of bias was assessed with ROBINS-I. Risk ratios (RRs) and 95% CIs were pooled in random effects meta-analyses. Certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). RESULTS: We included 18 cohort studies (1,164,774 participants). In cohort studies, combination therapy was associated with a lower risk of MACE (RR 0.56 [95% CI 0.43, 0.71]; low certainty of evidence) and the kidney composite endpoint (RR 0.48 [95% CI 0.32, 0.73]; very low certainty of evidence) relative to SGLT2 inhibitor or GLP-1 RA monotherapy. Combination therapy was also associated with a lower risk of all-cause mortality (RR 0.50 [95% CI 0.40, 0.63]; low certainty of evidence), cardiovascular mortality (RR 0.26 [95% CI 0.16, 0.43]; low certainty of evidence) and hospitalisation for heart failure (RR 0.67 [95% CI 0.64, 0.71]; moderate certainty of evidence). Although safety data could not be pooled due to lack of events, no differences were observed in the risk of severe hypoglycaemia, diabetic ketoacidosis, genitourinary infections and gastrointestinal side effects. No data were reported on the risk of serious adverse events or major adverse limb events. CONCLUSIONS/INTERPRETATION: Observational studies suggest that combining an SGLT2 inhibitor and a GLP-1 RA in type 2 diabetes may lower the risk of MACE, all-cause and cardiovascular mortality, hospitalisation for heart failure and kidney composite endpoints compared with monotherapy with either drug. Of course, residual confounding cannot be overcome but results support the need for future randomised trials of combined vs monotherapy. REGISTRATION: PROSPERO registration no. CRD42024532383.
引用
- Colombijn JMT, de Leijer JF, Visseren FLJ, et al. Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 2025. PMID: 41117973. doi:10.1007/s00125-025-06565-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。